Barclays Lowers Tvardi Therapeutics (NASDAQ:TVRD) Price Target to $4.00

Tvardi Therapeutics (NASDAQ:TVRD) had its price objective decreased by research analysts at Barclays from $5.00 to $4.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 38.41% from the company’s previous close.

TVRD has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Hold” and a consensus target price of $46.00.

Tvardi Therapeutics Price Performance

Shares of NASDAQ TVRD traded down $0.29 during mid-day trading on Wednesday, hitting $2.89. 98,692 shares of the company’s stock traded hands, compared to its average volume of 63,048. The company’s 50-day moving average is $3.81 and its two-hundred day moving average is $9.00. The company has a market capitalization of $27.11 million, a P/E ratio of -0.30 and a beta of 0.14. Tvardi Therapeutics has a 1 year low of $2.81 and a 1 year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.23).

Institutional Investors Weigh In On Tvardi Therapeutics

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Headlands Technologies LLC purchased a new position in Tvardi Therapeutics during the second quarter valued at approximately $80,000. New York State Common Retirement Fund bought a new position in Tvardi Therapeutics in the second quarter worth approximately $92,000. Finally, Arax Advisory Partners lifted its holdings in Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after buying an additional 6,173 shares during the period. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.